Exubrion Therapeutics®, the company behind Synovetin OA®, has promoted Gregory Taglialatela, MBA, to Chief Commercial Officer, effective July 1, 2026.
Exubrion Therapeutics®, the company behind Synovetin OA®, has promoted Gregory Taglialatela, MBA, to Chief Commercial Officer, effective July 1, 2026.